Jin-Hee Park; Sun Hyoung Bae; Yong-Sik Jung; Young-Mi Jung

doi:10.4040/jkan.2015.45.1.118

Articles

Page Path: HOME > J Korean Acad Nurs > Volume 45(1); 2015 > Article

Original Article
Prevalence and Characteristics of Chemotherapy-related Cognitive Impairment in Patients with Breast Cancer: Jin-Hee Park, Sun Hyoung Bae, Yong-Sik Jung, Young-Mi Jung; Journal of Korean Academy of Nursing 2015;45(1):118-128.
DOI: https://doi.org/10.4040/jkan.2015.45.1.118
Published online: February 27, 2015

¹College of Nursing, Ajou University, Suwon, Korea.

²Department of Nursing, College of Medicine, Dong-A University, Busan, Korea.

³Department of Surgery, School of Medicine, Ajou University, Suwon, Korea.

Address reprint requests to: Bae, Sun Hyoung. Department of Nursing, College of Medicine, Dong-A University, 32 Daesingongwon-ro, Seo-gu, Busan 602-714, Korea. Tel: +82-51-240-2877, Fax: +82-51-240-2920, shyoung@dau.ac.kr

• Received: September 12, 2014 • Revised: October 7, 2014 • Accepted: January 13, 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution NoDerivs License. (http://creativecommons.org/licenses/by-nd/4.0/) If the original work is properly cited and retained without any modification or reproduction, it can be used and re-distributed in any format and medium.

22 Views
1 Download
17 Scopus

prev next

Full Article

Download PDF

Abstract
NOTES
REFERENCES

Abstract

Purpose
Evidence suggests that some patients with breast cancer experience cognitive difficulties following chemotherapy. This longitudinal study was done to examine the prevalence of cognitive impairment and trajectory of cognitive function over time in women with breast cancer, who received adjuvant chemotherapy.
Methods
Participants were 137 patients with breast cancer. They completed neuropsychological tests and the Functional Assessment of Cancer Therapy-Cognitive Function before adjuvant therapy (pretest), toward the end of adjuvant therapy (posttest), and 6 months after the completion of adjuvant therapy (follow-up test). Of the patients, 91 were treated with adjuvant chemotherapy and 46 patients who did not receive chemotherapy made up the comparison group. A reliable-change index and repeated-measure ANOVA were used for statistical analyses.
Results
At the posttest point, over 30% of patients showed complex cognitive impairment and reported greater difficulty in subjective cognitive function. At the follow-up test point, 22.0% of patients exhibited complex cognitive impairment and 30.8% of patients complained of subjective cognitive impairment. Repeated-measure ANOVA showed significant decreases after receiving chemotherapy followed by small improvements 6 months after the completion of chemotherapy in cognitive domains of change for attention and concentration, memory, executive function, and subjective cognitive function.
Conclusion
These results suggest that chemotherapy in patients with breast cancer may be associated with objective and subjective cognitive impairments. Further studies are needed to explore the potential risk factors and predictor of chemotherapy-related cognitive changes. Also nursing interventions for prevention and intervention of cognitive impairments should be developed and tested.
Keywords: Breast neoplasms; Adjuvant chemotherapy; Attention; Memory; Executive function

This work was supported by the National Research Foundation of Korea (KRF) funded by the Korea government (MEST) (2011-0012145).

REFERENCES

1. Jung KW, Won YJ, Kong HJ, Oh CM, Lee DH, Lee JS. Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2011. Cancer Res Treat. 2014;46(2):109–123. Article PubMed PMC
2. Munir F, Burrows J, Yarker J, Kalawsky K, Bains M. Women's perceptions of chemotherapy-induced cognitive side affects on work ability: A focus group study. J Clin Nurs. 2010;19(9-10):1362–1370. Article PubMed
3. Matsuda T, Takayama T, Tashiro M, Nakamura Y, Ohashi Y, Shimozuma K. Mild cognitive impairment after adjuvant chemotherapy in breast cancer patients-evaluation of appropriate research design and methodology to measure symptoms. Breast Cancer. 2005;12(4):279–287.Article PubMed
4. Park JH, Bae SH. A meta-analysis of chemotherapy related cognitive impairment in patients with breast cancer. J Korean Acad Nurs. 2012;42(5):644–658. Article PubMed
5. Ahles TA, Saykin AJ. Breast cancer chemotherapy-related cognitive dysfunction. Clin Breast Cancer. 2002;3:Suppl 3. S84–S90.PubMed
6. Hutchinson AD, Hosking JR, Kichenadasse G, Mattiske JK, Wilson C. Objective and subjective cognitive impairment following chemotherapy for cancer: A systematic review. Cancer Treat Rev. 2012;38(7):926–934. Article PubMed
7. Myers JS. Chemotherapy-related cognitive impairment: The breast cancer experience. Oncol Nurs Forum. 2012;39(1):E31–E40. Article PubMed
8. Collins B, Mackenzie J, Kyeremanteng C. Study of the cognitive effects of chemotherapy: Considerations in selection of a control group. J Clin Exp Neuropsychol. 2013;35(4):435–444. Article PubMed
9. Jansen CE, Cooper BA, Dodd MJ, Miaskowski CA. A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. Support Care Cancer. 2011;19(10):1647–1656. Article PubMed PDF
10. Jim HS, Donovan KA, Small BJ, Andrykowski MA, Munster PN, Jacobsen PB. Cognitive functioning in breast cancer survivors: A controlled comparison. Cancer. 2009;115(8):1776–1783. Article PubMed
11. Hermelink K, Untch M, Lux MP, Kreienberg R, Beck T, Bauerfeind I, et al. Cognitive function during neoadjuvant chemotherapy for breast cancer: Results of a prospective, multicenter, longitudinal study. Cancer. 2007;109(9):1905–1913. Article PubMed
12. Ouimet LA, Stewart A, Collins B, Schindler D, Bielajew C. Measuring neuropsychological change following breast cancer treatment: An analysis of statistical models. J Clin Exp Neuropsychol. 2009;31(1):73–89. Article PubMed
13. Vearncombe KJ, Rolfe M, Wright M, Pachana NA, Andrew B, Beadle G. Predictors of cognitive decline after chemotherapy in breast cancer patients. J Int Neuropsychol Soc. 2009;15(6):951–962. Article PubMed
14. Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: Results of a prospective, randomized, longitudinal trial. Cancer. 2004;100(11):2292–2299. Article PubMed
15. Janelsins MC, Kesler SR, Ahles TA, Morrow GR. Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry. 2014;26(1):102–113. Article PubMed PMC
16. Avisar A, River Y, Schiff E, Bar-Sela G, Steiner M, Ben-Arye E. Chemotherapy-related cognitive impairment: Does integrating complementary medicine have something to add? Review of the literature. Breast Cancer Res Treat. 2012;136(1):1–7. Article PubMed PDF
17. Ferguson RJ, McDonald BC, Saykin AJ, Ahles TA. Brain structure and function differences in monozygotic twins: Possible effects of breast cancer chemotherapy. J Clin Oncol. 2007;25(25):3866–3870. Article PubMed
18. Stewart A, Bielajew C, Collins B, Parkinson M, Tomiak E. A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol. 2006;20(1):76–89. Article PubMed
19. Jansen CE, Miaskowski CA, Dodd MJ, Dowling GA. A meta-analysis of the sensitivity of various neuropsychological tests used to detect chemotherapy-induced cognitive impairment in patients with breast cancer. Oncol Nurs Forum. 2007;34(5):997–1005. Article PubMed
20. Tager FA, McKinley PS, Schnabel FR, El-Tamer M, Cheung YK, Fang Y, et al. The cognitive effects of chemotherapy in post-menopausal breast cancer patients: A controlled longitudinal study. Breast Cancer Res Treat. 2010;123(1):25–34. Article PDF
21. Wagner LI, Sweet J, Butt Z, Lai JS, Cella D. Measuring patient self-reported cognitive function: Development of the functional assessment of cancer therapy-cognitive function instrument. J Support Oncol. 2009;7(6):W32–W39.
22. Chelune GJ, Naugle RI, Lüders H, Sedlak J, Awad IA. Individual change after epilepsy surgery: Practice effects and base-rate information. Neuropsychology. 1993;7(1):41–52. Article
23. Lezak MD, Howieson DB, Loring DW, Hannay J, Fischer JS. Neuropsychological assessment. 4th ed. New York, NY: Oxford University Press; 2004.
24. Von Ah D, Habermann B, Carpenter JS, Schneider BL. Impact of perceived cognitive impairment in breast cancer survivors. Eur J Oncol Nurs. 2013;17(2):236–241. Article PubMed
25. Cheung YT, Tan EH, Chan A. An evaluation on the neuropsychological tests used in the assessment of postchemotherapy cognitive changes in breast cancer survivors. Support Care Cancer. 2012;20(7):1361–1375. Article PubMed PDF
26. Moon S, Kim SH, Kim MJ. Perceived cognitive function and related factors in Korean women with breast cancer. Asian Nurs Res. 2011;5(2):141–150. Article
27. Kaiser J, Bledowski C, Dietrich J. Neural correlates of chemotherapy-related cognitive impairment. Cortex. 2014;54:33–50. Article PubMed
28. Collins B, Mackenzie J, Stewart A, Bielajew C, Verma S. Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment. Psychooncology. 2009;18(2):134–143. Article PubMed
29. Myers JS, Teel C. Oncology nurses' awareness of cognitive impairment secondary to chemotherapy. Clin J Oncol Nurs. 2008;12(5):725–729. Article PubMed
30. Chung BY, Cho EJ. Correlates influencing cognitive impairment in breast cancer patients receiving chemotherapy. Asian Oncol Nurs. 2012;12(3):221–229. Article PDF

Table 1

Homogeneity Tests between Chemotherapy Group and Comparison Group (N =137)

^*Fishers exact test; ^†Body mass index classified according to World Health Organization Western Pacific Region, International Association for the Study of Obesity, & International Obesity Task Force (2000); CTx=Chemotherapy; DCIS=Ductal carcinoma in situ; HRTx=Hormone therapy; KRW=Korean Won; M=Mean; MRM=Modified radical mastectomy; PM=Partial mastectomy; RTx=Radiotherapy; SD=Standard deviation; TM=Total mastectomy.

Table 2

Prevalence of Chemotherapy-Related Cognitive Impairment in Chemotherapy Group (N =91)

Table 3

Changes of Cognitive Function in Chemotherapy Group (N =91)

CI=Confidence interval; CogOth=Comments from others; CogPCA=Perceived cognitive abilities; CogPCI=Perceived cognitive impairments; CogQOL=Impact on quality of life; FACT-Cog=Functional assessment of cancer therapy-cognitive function; K-COWAT=Korean Controlled Oral Word Association Test; M=Mean; MD=Mean difference; SD=Standard deviation; SE=Standard error; SVLT=Seoul Verbal Learning Test; TMT=Trail making test.

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Prevalence and Characteristics of Chemotherapy-related Cognitive Impairment in Patients with Breast Cancer

J Korean Acad Nurs. 2015;45(1):118-128. Published online February 27, 2015

DOI: https://doi.org/10.4040/jkan.2015.45.1.118

XML Download

We recommend

Prevalence and Characteristics of Chemotherapy-related Cognitive Impairment in Patients with Breast Cancer

Table 1

Homogeneity Tests between Chemotherapy Group and Comparison Group (N =137)

Table 2

Prevalence of Chemotherapy-Related Cognitive Impairment in Chemotherapy Group (N =91)

Table 3

Changes of Cognitive Function in Chemotherapy Group (N =91)

Table 1 Homogeneity Tests between Chemotherapy Group and Comparison Group (N =137)

Table 2 Prevalence of Chemotherapy-Related Cognitive Impairment in Chemotherapy Group (N =91)

Table 3 Changes of Cognitive Function in Chemotherapy Group (N =91)